GrowGeneration Reports Third Quarter 2026 Financial Results

GrowGeneration Corp. (GRWG) filed an SEC Form 8-K — Regulation FD Disclosure. GrowGeneration Reports Third Quarter 2026 Financial Results Delivers Positive GAAP Net Income and $2.3 million of Adjusted EBITDA Proprietary Brand Sales Increase 19.3% Year-Over-Year, Reaching 40.6% of Cultivation and Gardening Revenue Gross Margin Expands 520 Basis Points to 32

Original reporting
Published Nov 10, 2026, 9:12 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 10, 2026, 9:16 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$GRWG
Bullish
high confidence
Mentioned
$GRWG
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$GRWGBullishMed
01

Why it matters

The earnings release shows a turnaround to profitability, margin expansion, and a tighter revenue outlook, which may attract value‑oriented investors.

02

Market read

The positive earnings and revised guidance could lift GRWG and related agritech stocks, though the modest revenue range tempers enthusiasm.

03

What to watch

Potential headwinds from supply‑chain disruptions and regulatory changes to indoor farming could affect future margins.

Relevance 6/10Novelty 7/10Timing: released with the Q3 filing today

Background

GrowGeneration Corp. (NASDAQ:GRWG) is a leading supplier of specialty products for controlled environment agriculture, reporting its third‑quarter 2026 financials via an SEC 8‑K filing.

Company-level read

Ticker impact

$GRWGBullishHigh confidence
Context

GrowGeneration reported Q3 2026 results with GAAP net income, positive Adjusted EBITDA and narrowed full-year revenue guidance to $163‑$165 million.

Expected impact

likely upward pressure as the market prices in higher margins and lower expenses.

Evidence & confidence

The company posted a GAAP profit, raised gross margin by 520 bps and cut operating costs, while also narrowing guidance, which typically supports the stock.

Market effects

Signals strength in the controlled‑environment agriculture sector as proprietary‑brand sales gain share.

North American specialty‑agriculture suppliers may see modest upside.

Limited to niche agritech investors.

Counterpoint

The guidance still caps revenue below prior year, and inventory remains high; a pullback is possible if cost cuts fall short.

Key entities

  • Darren Lampert

    Co‑Founder and CEO of GrowGeneration, quoted on the results.

Related articles

$GRWGMedAI 8/10

GrowGeneration Beats on Q2 Earnings, Hikes '26 Adjusted EBITDA View

GrowGeneration Corp. (GRWG) reported Q2 2026 results: a 3-cent per-share loss, narrower than the Zacks Consensus estimate of a 4-cent loss and versus an 8-cent loss a year earlier. Sales rose 5.5% to $43.2M. Adjusted EBITDA was $0.3M. The company raised full-year adjusted EBITDA guidance to $2–$3M and reaffirmed sales guidance of $162–$168M.

$GRWGMedAI 8/10

GrowGeneration Corp. Q2 2026 Earnings Call Summary

GrowGeneration Corp. reported a third straight quarter of YoY revenue growth, citing a shift to a commercial B2B platform and proprietary brands. Proprietary brand penetration reached 40% ahead of schedule. The company cut store and operating expenses 22% YoY and raised full-year 2026 adjusted EBITDA guidance to $2M-$3M, aided by expected Q3 IEPA tariff refunds. It repurchased 700,000 shares at $1.38.

$GRWGMedAI 8/10

GrowGeneration (GRWG) Q2 2026 Earnings Call Transcript

GrowGeneration (GRWG) reported Q2 2026 revenue of $43.2 million, up 5.5% year over year, with adjusted EBITDA of $0.3 million versus a $1.3 million loss a year earlier. Net loss narrowed to $2.0 million. Gross margin rose to 28.5%. Full-year 2026 guidance: revenue $162-$168 million and adjusted EBITDA $2-$3 million. Cash was $41 million with no debt.

$INOHighAI 8/10

Inovio Q3 2026 slides: VOCERYQ approval amid wider loss

Inovio Pharmaceuticals reported a Q3 2026 net loss of $49.2M, wider than expected, despite FDA approval of VOCERYQ. Shares fell 3.97% to $1.45, then another 10.34% after hours. Operating expenses declined 7% YoY, but non-cash losses increased. Cash reserves total $48.4M, with a runway into late 2027. VOCERYQ targets recurrent respiratory papillomatosis, showing 50-100% surgery reduction in trials. The company plans a Q1 2027 launch and European filings by year-end.